Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous i
A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), althou
In its second guidance on digital health technologies within a week, NICE has endorsed five remote monitoring devices for patients with Parkinson’s disease that can be use
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion ther
French pharma Servier has enlisted the aid of ‘digital twin’ specialist Aitia for a third time, adding a Parkinson’s disease project to their prior collaborations on pancr
Patient recruitment is now underway in a clinical trial of Newel Health’s digital therapeutic for Parkinson’s disease, which hopes to show it can enhance the efficacy of t
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin